1
Is likely to affect drug sensitivities to antiEGFR therapy in colorectal cancer regardless of BRAF mutational status. These data provide new insights into the molecular mechanisms underlying the oncogenesis of colorectal cancer. Few studies have investigated the relationship between BRAF mutations and altered miRNA expression in colorectal cancer. In contrast, a handful of studies have focused on